A new immunotherapy clinical trial at Seattle Children’s is now open for enrollment. The phase 1 clinical trial, called STRIvE-02, will study the safety and efficacy of a T-cell immunotherapy treatment for cancer patients with solid tumors.

About STRIvE-02:

Seattle Children’s doctors and researchers are leaders in developing chimeric antigen receptor (CAR) T-cell immunotherapies to treat children and young adults with relapsed or refractory solid tumors who are not likely to survive with standard treatments.

We reprogram the patient’s T cells to recognize and target the protein B7H3, which is expressed by many pediatric solid tumors. Patients do not need a tumor tissue screening prior to enrollment.

This trial is led by Dr. Navin Pinto. Pinto is a physician at the Cancer and Blood Disorders Center at Seattle Children’s Hospital and an investigator in the Center for Clinical and Translational Research at Seattle Children’s Research Institute.

Who can join the STRIvE studies? 

The STRIvE studies are for children and young adults who:

  • Have relapsed or refractory solid tumors
    • STRIvE-01: tumor must express EGFR
    • STRIvE-02: given high tumor B7H3 expression in most pediatric cancers, all relapsed/refractory solid tumor patients are potentially eligible
  • Are ages 0 to 26 years old

Find more details at our STRIvE webpage.

Contact us

For more information about STRIvE-02 or any of our immunotherapy trials, call 206-987-2106 or send us an email.

More about T-cell immunotherapy at Seattle Children’s

STRIvE is one of Seattle Children’s 10 T-cell immunotherapy trials focused on using the immune system to offer better treatment options for children and young adults with cancers, including:

Read more about how T-cell immunotherapy works.